Highlights
- Cogstate signed US$25.1 million of net sales contracts in the September 2026 quarter.
- FY26 Revenue was US$60.9 million and EBITDA was US$18.3 million.
- FY26 contracted future revenue stood at US$118.5 million.
- Its FY26 investor briefing outlined AI-enabled clinical-trial workflow initiatives.
Cogstate supplies digital cognitive assessments, clinical-trial measurement services and central nervous system endpoint quality solutions to pharmaceutical research programmes. Cogstate (ASX:CGS) closed at AUD 3.64 on November 18, 2026, a rise of 1.11% during the session. Its October 2026 Business update reported September-quarter sales contracts, following FY26 financial results that detailed revenue, profitability and contracted future work across clinical trials.
Clinical Trial Services and Assessment Technology
Cogstate provides cognitive assessments and related scientific oversight for central nervous system trials. Pharmaceutical sponsors use these services to support consistent testing, data quality and endpoint interpretation across clinical sites. The company also reports a healthcare business based on its cognitive assessment products. These activities involve different customer pathways and commercial arrangements.
Contract signing, delivery of trial services and revenue recognition are not the same event. A new contract represents future work subject to the project’s schedule, while reported revenue reflects services performed under applicable accounting rules. This distinction is particularly important where Clinical Trials proceed over several periods, change scope or experience delays.
September-Quarter Contract Update
In its October 2026 business update, Cogstate said net sales contracts executed during the September quarter totalled US$25.1 million. The company described an approach that combines its scientific expertise with channel partnerships, allowing trial sponsors to access its endpoint services alongside other technology providers. Signed contracts add to the potential delivery pipeline but do not constitute immediate cash receipts or earnings.
Cogstate’s FY26 investor presentation reported US$89.0 million in contracts signed across the financial year and US$118.5 million in contracted future revenue at June 2026. Of that balance, US$48.3 million was identified for expected recognition in FY27. These figures reflect contracted work and scheduling assumptions rather than a guarantee that all revenue will be recognised at the originally anticipated time.
FY26 Revenue and Profitability
For FY26, Cogstate reported total revenue of US$60.9 million, EBITDA of US$18.3 million and net profit after tax of US$11.9 million. The Annual Report identified US$58.4 million of clinical trials revenue and approximately US$2.5 million of healthcare revenue. Financial disclosures also showed US$34.8 million of cash at year-end and no debt, according to the investor briefing.
The results provide a reference point for examining the new financial year. Contract execution can precede implementation, and activity during an individual quarter may not correspond directly to reported Earnings in that quarter. Operating expenditure, trial start dates and the proportion of revenue provided by clinical trial services influence profitability.
Technology Investment and Risks
Cogstate described planned AI-enabled rater Training and central monitoring initiatives in its FY26 investor briefing. The presentation outlined a two-year build-out spanning FY27 and FY28, involving product and platform investment. The projects are development plans rather than completed product outcomes. Their commercial and operating benefits will depend on adoption and successful implementation.
Trial timing, sponsor budgets, protocol revisions, contract cancellations and workforce availability are operating considerations. The company also relies on accurate assessment delivery and the integrity of clinical research data. Investors can monitor conversion of contracted revenue, new contracts, research spending and the timing of platform releases.
Key Insights
Cogstate (ASX:CGS) began FY27 with substantial contracted work and reported US$25.1 million of net new sales contracts in the September quarter. Its FY26 revenue and profitability establish a financial baseline, while the technology roadmap introduces implementation costs and milestones to assess. Future results will clarify the conversion of contracts into recognised revenue.



_11_18_2026_07_37_18_094902.jpg)


Please wait processing your request...